Sam Gandy, MD, PhD, is Mount Sinai Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, Associate Director of the Mount Sinai Alzheimer's Disease Research Center in New York City, and Chairman Emeritus of the National Medical and Scientific Advisory Council of the Alzheimer's Association. Dr. Gandy is an international expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Alzheimer's. In 1989, Gandy and his team discovered the first drugs that could lower formation of amyloid. Dr. Gandy has written more than 150 original papers, chapters and reviews on this topic. Dr. Gandy has received continuous NIH funding for his research on amyloid metabolism since 1986.
Dr. Gandy is a member of the Faculty of 1000 Biology and serves as a Consulting Editor for The Journal of Clinical Investigation. He also serves on the Editorial Advisory Boards for the journals Public Library of Science-Medicine (PLoSM), Neurodegenerative Diseases, and Current Alzheimer Research. He is Associate Editor of the journals Molecular Neurodegeneration and Alzheimer Disease and Associated Disorders. From 1996-2006, Dr Gandy was Director of the Cold Spring Harbor Laboratories/Wellcome Trust Annual Summer Course on the Neurobiology of Human Neurological Disorders. In 2000, he became chief organizer for the Cold Spring Harbor Laboratories Bi-Annual Winter Biotechnology Conference on Therapeutic Opportunities in Neurodegenerative Diseases and continues in that role until 2010.
Dr. Gandy has appeared numerous times on television and in print, including:
In May 2009, Dr. Gandy was featured with other prominent research scientists as GQ's "Rockstars of Science". View the PDF. In addition, Dr. Gandy has spoken before Congress on several occasions (Click to view the PDF of transcript of 5/3/05, PDF of transcript of 3/20/07)
Dr. Gandy received both his MD and PhD at the Medical University of South Carolina. He completed an internship in Internal Medicine at the Columbia University College of Physicians & Surgeons and a residency in Neurology at Cornell University Medical College. Dr. Gandy completed postdoctoral training at The Rockefeller University, where, in 1991, he was appointed assistant professor in the laboratory of Paul Greengard, 2000 Laureate of the Nobel Prize in Physiology or Medicine. From 1992-1997, Gandy was Associate Professor of Neurology and Neuroscience at Cornell University Medical College. From 1997-2001, he was Professor of Psychiatry and of Cell Biology at New York University and The Nathan S. Kline Institute for Psychiatric Research. From 2001-2007, he served as Paul C. Brucker, M.D., Professor of Neuroscience at Jefferson Medical College and Founding Director of the Farber Institute for Neurosciences. In 2007, he assumed his current post as Mount Sinai Professor of Alzheimer's Disease Research at the Mount Sinai School of Medicine.
Cell Biology, Protein Trafficking & Sorting, Stem Cells
MD, Medical University of South Carolina
Internship, Internal Medicine
Columbia University College of Physicians & Surgeons
New York Hospital Cornell University Med Ctr
Arthur Cherkin Memorial Award in Geriatric Medicine
Current Students: John W. Steele IV, Hannah Brautigam
Postdoctoral Fellows: Soong Ho Kim, PhD, Rachel Lane, Ph.D.
Research Personnel: Alex Lublin, Ph.D. (Instructor), Carlos Thomas
Dr. Gandy is an international expert in the metabolism of the substance called amyloid that clogs the brain in patients with Alzheimer's. In 1989, Gandy and his team discovered the first drugs that could lower formation of amyloid. Dr. Gandy has written more than 150 original papers, chapters and reviews on this topic. Dr. Gandy has received continuous NIH funding for his research on amyloid metabolism since 1986. Dr. Gandy is Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Mount Sinai Alzheimer's Disease Research Center, and Chair, National Medical and Scientific Advisory Council of the Alzheimer's Association.
Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, Sewell MC, Aloysi A, Goldstein MA, Li C, Sano M, Gandy S. A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Molecular neurodegeneration 2014; 9.
Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, Santa-Maria I, Zimmer M, Aubry S, Steele JW, Kahler DJ, Dranovsky A, Arancio O, Crary JF, Gandy S, Noggle SA. Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. PloS one 2014; 9(1).
Gandy S, Haroutunian V, DeKosky ST, Sano M, Schadt EE. CR1 and the . Biological psychiatry 2013 Mar; 73(5).
Lane RF, Steele JW, Cai D, Ehrlich ME, Attie AD, Gandy S. Protein sorting motifs in the cytoplasmic tail of SorCS1 control generation of Alzheimer's amyloid-β peptide. The Journal of neuroscience : the official journal of the Society for Neuroscience 2013 Apr; 33(16).
De Gasperi R, Gama Sosa MA, Kim SH, Steele JW, Shaughness MC, Maudlin-Jeronimo E, Hall AA, Dekosky ST, McCarron RM, Nambiar MP, Gandy S, Ahlers ST, Elder GA. Acute blast injury reduces brain abeta in two rodent species. Frontiers in neurology 2012; 3.
Lane RF, St George-Hyslop P, Hempstead BL, Small SA, Strittmatter SM, Gandy S. Vps10 family proteins and the retromer complex in aging-related neurodegeneration and diabetes. The Journal of neuroscience : the official journal of the Society for Neuroscience 2012 Oct; 32(41).
Zhu L, Su M, Lucast L, Liu L, Netzer WJ, Gandy SE, Cai D. Dynamin 1 regulates amyloid generation through modulation of BACE-1. PloS one 2012; 7(9).
Zhu L, Zhong M, Zhao J, Rhee H, Caesar I, Knight EM, Volpicelli-Daley L, Bustos V, Netzer W, Liu L, Lucast L, Ehrlich ME, Robakis NK, Gandy SE, Cai D. Reduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model. The Journal of biological chemistry 2013 Nov; 288(44).
Gandy S, Haroutunian V, DeKosky ST, Sano M, Schadt EE. CR1 and the . Biological psychiatry 2013 Mar; 73(5).
Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annual review of medicine 2013; 64.
Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Molecular psychiatry 2013 Aug; 18(8).
Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Molecular psychiatry 2013 Aug; 18(8).
Kim SH, Knight EM, Saunders EL, Cuevas AK, Popovech M, Chen LC, Gandy S. Rapid doubling of Alzheimer's amyloid-β40 and 42 levels in brains of mice exposed to a nickel nanoparticle model of air pollution. F1000Research 2012; 1.
Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. The Journal of neuroscience : the official journal of the Society for Neuroscience 2010 Sep; 30(39).
Kim SH, Fraser PE, Westaway D, St George-Hyslop PH, Ehrlich ME, Gandy S. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. The Journal of neuroscience : the official journal of the Society for Neuroscience 2010 Mar; 30(11).
Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Annals of neurology 2010 Aug; 68(2).
Seeger M, Nordstedt C, Petanceska S, Kovacs DM, Gouras GK, Hahne S, Fraser P, Levesque L, Czernik AJ, George-Hyslop PS, Sisodia SS, Thinakaran G, Tanzi RE, Greengard P, Gandy S. Evidence for phosphorylation and oligomeric assembly of presenilin 1. Proceedings of the National Academy of Sciences of the United States of America 1997 May; 94(10).
Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proceedings of the National Academy of Sciences of the United States of America 1997 Apr; 94(8).
Xu H, Sweeney D, Greengard P, Gandy S. Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Proceedings of the National Academy of Sciences of the United States of America 1996 Apr; 93(9).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gandy during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.